Cencora, Inc. (NYSE:COR) Shares Purchased by United Bank

United Bank increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 4.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,601 shares of the company’s stock after acquiring an additional 225 shares during the period. United Bank’s holdings in Cencora were worth $1,261,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of COR. New Millennium Group LLC acquired a new stake in Cencora in the 2nd quarter worth about $26,000. TCTC Holdings LLC acquired a new stake in Cencora in the 1st quarter worth about $29,000. TFO Wealth Partners LLC acquired a new stake in Cencora in the 1st quarter worth about $30,000. LRI Investments LLC acquired a new stake in Cencora in the 1st quarter worth about $31,000. Finally, MFA Wealth Advisors LLC acquired a new stake in Cencora in the 2nd quarter worth about $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

COR has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Wells Fargo & Company raised their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Leerink Partners decreased their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Bank of America reissued a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, Robert W. Baird raised their target price on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Trading Up 0.3 %

COR opened at $248.42 on Friday. Cencora, Inc. has a one year low of $191.11 and a one year high of $251.00. The stock has a market capitalization of $48.95 billion, a PE ratio of 33.08, a P/E/G ratio of 1.49 and a beta of 0.44. The business’s 50 day moving average price is $231.95 and its 200 day moving average price is $230.84. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 6th. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.21 by $0.13. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $79.05 billion for the quarter, compared to analysts’ expectations of $77.68 billion. As a group, equities research analysts expect that Cencora, Inc. will post 13.64 EPS for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.